Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Subcutaneous Belimumab Improves Systemic Lupus Srythematosus Outcomes

Reuters Staff  |  May 1, 2018

NEW YORK (Reuters Health)—Subcutaneous belimumab improves outcomes in anti-dsDNA-positive hypocomplementemic patients with systemic lupus erythematosus (SLE), according to results from a Phase 3 randomized, controlled trial.

Intravenous belimumab is approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of patients with active, autoantibody-positive SLE who are receiving standard SLE therapy. The newer formulation aims to enable patients to self-administer subcutaneous belimumab.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Andrea Doria from the University of Padua, Italy, and colleagues investigated the efficacy and safety of subcutaneous belimumab in patients with SLE who were hypocomplementemic and anti-DNA-positive at baseline, a subgroup that previously showed greater benefits with belimumab IV treatment.

At Week 52, significantly more belimumab patients (64.6%) than placebo patients (47.2%) were responders, as defined by an SLE Responder Index score of 4, the researchers report in Arthritis & Rheumatology, online April 18.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

This response rate was higher than that seen for SLE patients who were not hypocomplementemic and anti-dsDNA-positive at baseline (58.8%).

Complement levels increased to a significantly greater extent among belimumab-treated patients than among those receiving placebo, whereas anti-dsDNA antibody levels did not change significantly in either group.

Severe flares were more common in the placebo group (31.5%) than in the belimumab group (14.1%), and a significantly greater proportion of patients in the belimumab group (44.8%) than in the placebo group (33.3%) had improvements in fatigue scores.

Treatment-emergent adverse events occurred with similar frequency in the belimumab and placebo groups, although serious adverse events were more common with placebo (23.1%) than with belimumab (13.3%).

Dr. Doria did not respond to a request for comments.

GlaxoSmithKline plc. designed, conducted and funded the study, and employed several of the authors.


Reference

  1. Doria A, Stohl W, Schwarting A, et al. Efficacy and safety of subcutaneous belimumab in anti-dsDNA-positive, hypocomplementemic patients with systemic lupus erythematosus. Arthritis Rheumatol. 2018 Apr 18. doi: 10.1002/art.40511. [Epub ahead of print]

Share: 

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:Arthritis & RheumatologybelimumabSLEsystemic lupus erythematosus (SLE)

Related Articles

    Belimumab Promising for Children with Lupus Nephritis

    October 6, 2022

    Belimumab is now FDA approved to treat children aged 5 years and older with active lupus nephritis, providing treatment options for pediatric patients at risk of developing renal damage.

    Laboratory Testing for Diagnosis, Management of Patients with Rheumatic Disease

    December 1, 2014

    A review of data on antinuclear antibodies and tests for rheumatoid arthritis

    Mitigate Risk and Increase Success of Lupus Clinical Trials

    August 1, 2010

    Design strategies from a Lupus Research Institute conference

    What’s New in SLE: Pathogenesis & Novel Therapies

    September 8, 2022

    Thomas Dörner, MD, reviewed the current state of systemic lupus erythematosus (SLE) management, providing updates on novel therapies and insights into the pathogenesis of SLE.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences